Takeda Pharmaceutical Company Limited

A global pharmaceutical company developing zasocitinib, a next-generation TYK2 inhibitor that claims stronger and more sustained enzyme inhibition than deucravacitinib. - Developing competing TYK2 inhibitor zasocitinib (TAK-279) in Phase 3

For most of the past decade, people with psoriatic arthritis who wanted a pill instead of an injection had one real option: Janus kinase (JAK) inhibitors, a class of oral drugs that the Food and Drug Administration (FDA) slapped with its strongest safety warning in 2021 after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death. On March 6, the FDA reached its decision deadline on whether to approve the first oral drug from a different class entirely—Bristol Myers Squibb's Sotyktu (deucravacitinib), a selective tyrosine kinase 2 (TYK2) inhibitor—for adults with active psoriatic arthritis, a condition that causes painful joint inflammation in roughly 1.5 million Americans.

Updated 8 hours ago

A global drugmaker betting that zasocitinib can be its next major immunology growth driver. - Sponsor and owner of zasocitinib; preparing FDA filings and broader immunology expansion

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don’t. Takeda’s once-daily TYK2 pill zasocitinib just cleared pivotal Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated Dec 18, 2025